Answer
Reduced Pseudomonas aeruginosa susceptibility to aztreonam was observed in clinical studies of Cayston (aztreonam lysine), but decreased susceptibility did not predict clinical efficacy in the 24-week active-controlled study.
Sources for this answer
- Cayston 75 mg powder and solvent for nebuliser solutionGilead Sciences Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 20Document updated
Sources checked